{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T23:28:28Z","timestamp":1717630108062},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.mehy.2012.06.033","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T04:23:01Z","timestamp":1342671781000},"page":"497-499","source":"Crossref","is-referenced-by-count":2,"title":["Cerebroventricular clozapine would be a viable treatment modality for clozapine-dependent schizophrenia patients with neutropenia"],"prefix":"10.1016","volume":"79","author":[{"given":"Joseph Martin","family":"Alisky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2012.06.033_b0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","article-title":"When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature","volume":"134","author":"Manu","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.mehy.2012.06.033_b0010","first-page":"85","article-title":"Can we prevent blood dyscrasia (leucopenia, thrombocytopenia) and epileptic seizures induced by clozapine?","volume":"22","author":"Herceg","year":"2010","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.mehy.2012.06.033_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.188.3.255","article-title":"Rechallenge with clozapine following leucopenia or neutropenia during previous therapy","volume":"188","author":"Dunk","year":"2006","journal-title":"BJP"},{"key":"10.1016\/j.mehy.2012.06.033_b0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.yic.0000062800.74434.6c","article-title":"Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis","volume":"18","author":"H\u00e4gg","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.mehy.2012.06.033_b0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2788.2006.00865.x","article-title":"Prevention of clozapine-induced granulocytopenia\/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia","volume":"51","author":"Rajagopal","year":"2007","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.mehy.2012.06.033_b0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/SMJ.0b013e318172f6c6","article-title":"Failure of filgrastim to prevent severe clozapine-induced agranulocytosis","volume":"101","author":"Majczenko","year":"2008","journal-title":"South Med J"},{"key":"10.1016\/j.mehy.2012.06.033_b0035","doi-asserted-by":"crossref","unstructured":"Nordin C, Alm\u00e9 B, Bondesson U. CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology (Berl) 1995;122:104\u20137.","DOI":"10.1007\/BF02246083"},{"key":"10.1016\/j.mehy.2012.06.033_b0040","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1097\/00001756-200212030-00040","article-title":"Brain size and grey matter volume in the healthy human brain","volume":"13","author":"L\u00fcders","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.mehy.2012.06.033_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/npp.1993.50","article-title":"Tissue concentrations of clozapine and its metabolites in the rat","volume":"9","author":"Baldessarini","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.mehy.2012.06.033_b0050","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1176\/appi.ajp.158.11.1930-a","article-title":"Gabapentin for clozapine-related seizures","volume":"158","author":"Landry","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2012.06.033_b0055","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/appi.ajp.157.3.482","article-title":"Gabapentin prophylaxis of clozapine-induced seizures","volume":"157","author":"Usiskin","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mehy.2012.06.033_b0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2210-2-6","article-title":"Central effects of clozapine in regulating micturition in anesthetized rats","volume":"2","author":"Vera","year":"2002","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.mehy.2012.06.033_b0065","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v57n1102","article-title":"Clozapine-induced urinary incontinence. incidence and treatment with ephedrine","volume":"57","author":"Fuller","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2012.06.033_b0070","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4088\/JCP.v58n0906c","article-title":"Oxybutynin and intranasal desmopressin for clozapine-induced urinary incontinence","volume":"58","author":"Lurie","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2012.06.033_b0075","first-page":"315","article-title":"Use of desmopressin to treat clozapine-induced nocturnal enuresis","volume":"55","author":"Steingard","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2012.06.033_b0080","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/pbc.21297","article-title":"Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system","volume":"50","author":"van de Glind","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.mehy.2012.06.033_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.surneu.2004.06.011","article-title":"Intrathecal chemotherapy for patients with meningeal carcinomatosis","volume":"63","author":"Yoshida","year":"2005","journal-title":"Surg Neurol"},{"key":"10.1016\/j.mehy.2012.06.033_b0090","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00381-012-1748-2","article-title":"Effects of the implantation of Ommaya reservoir in children with tuberculous meningitis hydrocephalus: a preliminary study","volume":"28","author":"Lin","year":"2012","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.mehy.2012.06.033_b0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MAJ.0b013e3181a3dac8","article-title":"A new method for the treatment of chronic fungal meningitis: continuous infusion into the cerebrospinal fluid for coccidioidal meningitis","volume":"338","author":"Berry","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.mehy.2012.06.033_b0100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jconrel.2004.01.005","article-title":"Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles","volume":"95","author":"Venkateswarlu","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.mehy.2012.06.033_b0105","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/0024-3205(85)90357-1","article-title":"CSF distribution of morphine, methadone and sucrose after intrathecal injection","volume":"37","author":"Payne","year":"1985","journal-title":"Life Sci"},{"issue":"Suppl","key":"10.1016\/j.mehy.2012.06.033_b0110","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1007\/BF00442556","article-title":"Clozapine\u2013pharmacokinetic investigations and biochemical effects in man","volume":"99","author":"Ackenheil","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.mehy.2012.06.033_b0115","first-page":"8","article-title":"CT-guided stereotactic placement of ventricular cannula","volume":"49","author":"Grode","year":"1984","journal-title":"Bull Clin Neurosci"},{"key":"10.1016\/j.mehy.2012.06.033_b0120","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/YCT.0b013e318205e1c0","article-title":"Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms","volume":"27","author":"Martinotti","year":"2011","journal-title":"J ECT"},{"key":"10.1016\/j.mehy.2012.06.033_b0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neulet.2011.01.039","article-title":"Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation","volume":"491","author":"Pedrini","year":"2011","journal-title":"Neurosci Lett"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987712003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T02:54:39Z","timestamp":1542855279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987712003106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0306987712003106"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2012.06.033","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}